Key data
Open—
From 52W high—
Volume—
Market cap—
P/E (TTM)—
P/S (TTM)—
Div yield—
Key data
Open
—
From 52W high
—
Volume
—
Market cap
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
SummaryUpdated Jun 1, 2026
Arbutus Biopharma Corporation (NASDAQ:ABUS) is a biopharmaceutical company founded in 2007 and headquartered in Warminster, Pennsylvania. Originally known as Tekmira Pharmaceuticals Corporation, the company changed its name to Arbutus Biopharma in July 2015. The company focuses on developing novel therapeutics primarily for chronic Hepatitis B virus infection, with additional research programs targeting coronaviruses including SARS-CoV-2. Arbutus has evolved from a broader drug delivery platform company into a specialized biotechnology firm with a concentrated focus on developing what it aims to be a functional cure for chronic Hepatitis B.
Latest newsMore news →
Arbutus Biopharma Corporation announced plans to repurchase up to US$230 million of its common shares through a modified Dutch Auction tender offer at a price between US$5.00 and US$5.75 per share, expected to commence on August 24, 2026 and expire on September 29, 2026.30d agoArbutus Biopharma reported its financial results for the second quarter of 2026, maintaining a strong financial position with cash, cash equivalents, and marketable securities of $92.6 million as of June 30, 2026.39d agoGenevant and Arbutus received $950 million from Moderna in July 2026 under a $2.25 billion settlement, with additional $1.3 billion contingent on appeal resolution, and filed new international lawsuits against Pfizer and BioNTech covering 21 jurisdictions.45d ago